The Medicines Co. (MDCO) Receives Outperform Rating from Leerink Swann
The Medicines Co. (NASDAQ:MDCO)‘s stock had its “outperform” rating reissued by Leerink Swann in a research report issued on Saturday.
MDCO has been the topic of several other reports. Royal Bank Of Canada reaffirmed a “buy” rating on shares of The Medicines in a report on Tuesday, July 12th. Citigroup Inc. reaffirmed a “hold” rating on shares of The Medicines in a report on Tuesday, August 2nd. Cowen and Company reaffirmed a “buy” rating and issued a $45.00 price objective on shares of The Medicines in a report on Friday, August 5th. Bank of America Corp. reaffirmed a “buy” rating on shares of The Medicines in a report on Tuesday, July 12th. Finally, Guggenheim upped their price objective on shares of The Medicines from $45.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, July 27th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $47.33.
The Medicines (NASDAQ:MDCO) opened at 35.41 on Friday. The company’s market capitalization is $2.47 billion. The Medicines has a 52-week low of $27.50 and a 52-week high of $43.00. The firm has a 50-day moving average of $38.65 and a 200 day moving average of $36.24.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/08/the-medicines-co-mdco-receives-outperform-rating-from-leerink-swann.html
The Medicines (NASDAQ:MDCO) last released its earnings results on Wednesday, July 27th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.54. The company had revenue of $54.70 million for the quarter, compared to the consensus estimate of $41.93 million. The Medicines had a negative net margin of 90.33% and a negative return on equity of 34.20%. The Medicines’s revenue was down 26.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.65) EPS. Equities analysts predict that The Medicines will post ($1.36) earnings per share for the current fiscal year.
In other The Medicines news, Director Hiroaki Shigeta sold 3,849 shares of the company’s stock in a transaction on Monday, July 11th. The shares were sold at an average price of $38.50, for a total transaction of $148,186.50. Following the completion of the transaction, the director now directly owns 23,547 shares in the company, valued at $906,559.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Clive Meanwell sold 1,377 shares of the company’s stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $40.00, for a total transaction of $55,080.00. Following the transaction, the chief executive officer now owns 339,168 shares of the company’s stock, valued at $13,566,720. The disclosure for this sale can be found here. Company insiders own 7.90% of the company’s stock.
A number of institutional investors have recently bought and sold shares of MDCO. Bridger Management LLC bought a new position in The Medicines during the first quarter worth $98,528,000. First Eagle Investment Management LLC bought a new position in The Medicines during the second quarter worth $18,668,000. Vanguard Group Inc. boosted its position in The Medicines by 3.9% in the second quarter. Vanguard Group Inc. now owns 5,423,391 shares of the company’s stock worth $182,388,000 after buying an additional 202,392 shares in the last quarter. UBS Asset Management Americas Inc. boosted its position in The Medicines by 10.9% in the first quarter. UBS Asset Management Americas Inc. now owns 2,053,184 shares of the company’s stock worth $65,230,000 after buying an additional 201,809 shares in the last quarter. Finally, Bank of Montreal Can bought a new position in The Medicines during the second quarter worth $6,288,000.
About The Medicines
The Medicines Company is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Co. and related companies with MarketBeat.com's FREE daily email newsletter.